Risk Perception in Multiple Sclerosis

Completed

Conditions studied: Multiple Sclerosis

In brief

This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.

Key facts

Study ID

NCT05528666

Run by

Novartis Pharmaceuticals

People needed

4361

Starts

2021-09-09

Expected to finish

2021-09-17

Last updated by the study team

2022-11-08

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients included in the database with a diagnosis of RRMS and SPMS.
• Patients with current treatment at the index date.
• Patients with previous treatment at the index date.
• Patients to whom the physician decided to switch the treatment from the previous treatment to current treatment at the index date.
• Patients (males \& females) with 18 years or older at index date.

You may not qualify if…

• Patients included in the database with the diagnosis of primary progressive MS (PPMS).
• Patients with other major neurological or psychiatric condition, which could potentially hinder the analysis.

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.